相关参考文献
注意:仅列出部分参考文献,下载原文获取全部文献信息。Safety, tolerability, and immunogenicity of an inactivated SARS-CoV-2 vaccine in healthy adults aged 18-59 years: a randomised, double-blind, placebo-controlled, phase 1/2 clinical trial
Yanjun Zhang et al.
LANCET INFECTIOUS DISEASES (2021)
Statin Therapy and Mortality of Hepatocellular Carcinoma
Shih-Wei Lai
CLINICAL GASTROENTEROLOGY AND HEPATOLOGY (2020)
Neutrophil-to-Lymphocyte Ratio (NLR), Platelet-to-Lymphocyte Ratio (PLR), and Outcomes with Nivolumab in Pretreated Non-Small Cell Lung Cancer (NSCLC): A Large Retrospective Multicenter Study
Alessandro Russo et al.
ADVANCES IN THERAPY (2020)
Efficacy of chemotherapy and atezolizumab in patients with non-small-cell lung cancer receiving antibiotics and proton pump inhibitors: pooled post hoc analyses of the OAK and POPLAR trials
M. Chalabi et al.
ANNALS OF ONCOLOGY (2020)
Association of Aspirin with Hepatocellular Carcinoma and Liver-Related Mortality
Tracey G. Simon et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Statins reduce the progression of non-advanced adenomas to colorectal cancer: a postcolonoscopy study in 187 897 patients
Ka-Shing Cheung et al.
GUT (2019)
Serum Lactate Dehydrogenase Before Nivolumab Treatment Could Be a Therapeutic Prognostic Biomarker for Patients With Metastatic Clear Cell Renal Cell Carcinoma
Suguru Shirotake et al.
ANTICANCER RESEARCH (2019)
Diabetes Increases Risk of Gastric Cancer After Helicobacter pylori Eradication: A Territory-Wide Study With Propensity Score Analysis
Ka Shing Cheung et al.
DIABETES CARE (2019)
Application of Big Data analysis in gastrointestinal research
Ka-Shing Cheung et al.
WORLD JOURNAL OF GASTROENTEROLOGY (2019)
Gut microbiome affects the response to anti-PD-1 immunotherapy in patients with updates hepatocellular carcinoma
Yi Zheng et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
Gut microbiome influences efficacy of PD-1-based immunotherapy against epithelial tumors
Bertrand Routy et al.
SCIENCE (2018)
Negative association of antibiotics on clinical activity of immune checkpoint inhibitors in patients with advanced renal cell and non-small-cell lung cancer
L. Derosa et al.
ANNALS OF ONCOLOGY (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
Global cancer statistics 2018: GLOBOCAN estimates of incidence and mortality worldwide for 36 cancers in 185 countries
Freddie Bray et al.
CA-A CANCER JOURNAL FOR CLINICIANS (2018)
Nivolumab in patients with advanced hepatocellular carcinoma (CheckMate 040): an open-label, non-comparative, phase 1/2 dose escalation and expansion trial
Anthony B. El-Khoueiry et al.
LANCET (2017)
T-cell invigoration to tumour burden ratio associated with anti-PD-1 response
Alexander C. Huang et al.
NATURE (2017)
Proton pump inhibitors affect the gut microbiome
Floris Imhann et al.
GUT (2016)
Proton pump inhibitors alter the composition of the gut microbiota
Matthew A. Jackson et al.
GUT (2016)
Mutational landscape determines sensitivity to PD-1 blockade in non-small cell lung cancer
Naiyer A. Rizvi et al.
SCIENCE (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Balance diagnostics for comparing the distribution of baseline covariates between treatment groups in propensity-score matched samples
Peter C. Austin
STATISTICS IN MEDICINE (2009)